Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams bought 48,100 shares of the stock in a transaction on Friday, November 13th. The shares were bought at an average price of $0.99 per share, for a total transaction of $47,619.00. Following the completion of the transaction, the director directly owned 36,960,836 shares of the company’s stock, valued at $36,591,227.64. This trade represents a 0.13% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Vivani Medical Trading Up 1.0%
Shares of Vivani Medical stock opened at $1.02 on Tuesday. The company has a 50-day moving average of $1.17 and a two-hundred day moving average of $1.24. Vivani Medical, Inc. has a 12-month low of $0.80 and a 12-month high of $1.66. The stock has a market cap of $92.00 million, a PE ratio of -3.19 and a beta of 2.51.
Vivani Medical (NASDAQ:VANI – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01.
Analyst Upgrades and Downgrades
Several analysts have issued reports on VANI shares. Wall Street Zen downgraded shares of Vivani Medical from a “hold” rating to a “sell” rating in a report on Sunday. Weiss Ratings reissued a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.75.
Get Our Latest Report on Vivani Medical
About Vivani Medical
Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.
Further Reading
- Five stocks we like better than Vivani Medical
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
